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(MMR). The model assumes stabilized prices of second-generation TKIs, but dis-
counts the price of imatinib: 100% for first 6-months; 60-80% for second 6-months; 
and 10-30% thereafter. For each drug, tolerance, efficacy and the probabilities of 
treatment choice, switching and failure were drawn from published clinical tri-
als. Quality-adjusted life years (QALYs) were based on U. K. preference weights 
(Szabo et al. 2010). According to Hoyle et al. (2011), direct medical costs per patient 
were: £20,244 for imatinib; and ~£30,000 for dasatinib and nilotinib. Additional 
costs included patient monitoring and allogeneic transplantation. Costs and QALYs 
were discounted at 3% (British Pounds Sterling (£); 2013). Sensitivity analyses tested 
parameters for impact on results at a willingness-to-pay of £50,000/QALY. Results: 
Step-therapy costs less and offers clinically-equivalent utility (£62,388; 2.864 QALYs) 
compared to physician-choice (£71,268; 2.879 QALYs), at an ICER of £592,000/QALY. 
The results are robust to changes based on univariate analyses of each parameter. 
Multivariate probabilistic sensitivity analyses found step-therapy cost-effective 
in 99.9% of 10,000 Monte Carlo simulations. ConClusions: When imatinib loses 
patient protection between 2015-2016 throughout Europe, it will be the cost-effective 
initial treatment strategy for CML compared to second-generation TKIs.
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BACkgRound: Invasive fungal infections (IFIs) are an important cause of morbidity 
and mortality in immunocompromised patients. Based on the pathogen identifica-
tion status, either empirical (without diagnosis) or targeted (with diagnosis) anti-
fungal therapy is administered to symptomatic patients (e.g. with fever). Several 
antifungal agents are available and their cost-effectiveness is often evaluated 
using decision analytic models (DAMs). oBjeCtives: The objective was to review 
all published DAMs used in economic evaluations of empirical/targeted antifungal 
treatments for IFIs. This approach is novel as previous reviews were either patho-
gen or agent-specific. Methods: A review was conducted in MEDLINE/EMBASE 
to identify all economic evaluations that included DAMs published until 1-1-2014. 
Previous reviews were checked for additional studies. Non-English and studies of 
prophylactic treatment were excluded. Data extracted included: population, indica-
tion, comparators, model structure, time horizon, outcomes, events, year, country, 
and sponsorship. Results: Overall, 24 published economic evaluations including 
a DAM were identified. 54% (n= 13) were for targeted treatments and the remaining 
(n= 11) for empirical treatments. 62% of the DAMs on targeted treatments (n= 8) 
focused on invasive pulmonary aspergillosis and the remaining 38% (n= 5) on inva-
sive candiasis/candidemia. The majority (73%, n= 8) of DAMs evaluating empirical 
treatments focused on patients with persistent fever/febrile neutropenia. Lipid for-
mulation amphotericin-B was a comparator in 46% (n= 11) of the studies, followed by 
caspofungin in 42% (n= 10) and voriconazole in 42% (n= 10). 92% of the DAMs (n= 22) 
included only a decision tree, whereas the remaining 8% (n= 2) embedded a life-
time Markov model. The majority (54%, n= 13) had a hospital perspective and time 
horizon of less than 12 weeks (54%, n= 14). Only one study utilized real-world data.  
ConClusions: There are major differences in the modeling approach, time horizon, 
comparator (s), treatment sequences and outcomes of published economic evalu-
ations in IFI. A list of minimal, consensus-based methodological and structural 
requirements for DAMs on antifungal treatments of IFIs, elicited from key experts 
is needed.
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oBjeCtives: To evaluate the cost-effectiveness of expanding the Norwegian HPV 
vaccination program to catch-up females and 12 years old boys. Methods: We 
systematically searched the literature for randomized clinical trials (RCTs) that exam-
ined the effect of HPV vaccines on cancer mortality and incidence, precancerous 
stages and serious adverse events. We assessed selected publications for potential 
risk of bias, and the overall quality of the evidence for each outcome using GRADE. 
We adapted a published economic model to the Norwegian setting with respect to 
incidence of HPV-related outcomes, costs and quality adjusted life years (QALYs) 
lost from HPV-related diseases. The cost utility analysis reported results in Euros/
QALY gained in both a public health budget and a societal perspective. Results: We 
included 46 publications reporting on 13 RCTs for young women, and 3 on 2 RCT for 
boys (maximum follow-up period: three-four years). We found a borderline protective 
effect of HPV catch-up vaccination on all CIN2+, with a pooled risk ratio (RR) of 0.80 
(95% CI: 0.62-1.02) for a follow-up period of 4 years. HPV catch-up vaccination was 
associated with a reduction in VIN2+ and VaIN2+ lesions, and genital warts. No dif-
ference in risk of serious adverse events was seen in vaccinated participants versus 
unvaccinated women (pooled RR of 0.99 (0.91-1.08)). We are currently reviewing the 
studies on boys. From a public health budget perspective, catch-up vaccination led 
to higher costs and health gains and an ICER= 70371€ . From a societal perspective, 
the incremental costs were lower, resulting in an ICER= 67365€ . ConClusions: This 
systematic review indicates that a HPV catch-up vaccination could be beneficial and 
cost-effective for young women. The long-term effect of such a vaccination, and its 
effect on cancer incidence and mortality is still unclear.
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erlotinib). Efficacy data were based on the TORCH and TAX317 randomised con-
trolled trials. Cost data were obtained from NHS Reference Costs, British National 
Formulary list prices and other publically-available sources. Results: In the base-
case analysis, the estimated incremental cost-effectiveness ratio exceeded the 
NICE willingness-to-pay threshold of £20,000 per quality-adjusted life year gained. 
Univariate and probabilistic sensitivity analyses suggested the results were robust 
to parameter changes, showing greatest sensitivity to variation in overall survival 
parameters. ConClusions: Our model suggests that, from the perspective of the 
UK NHS, an EGFR-TK mutation status-guided treatment strategy across first- and 
second-line treatment of NSCLC is not cost-effective compared with a strategy not 
dependent on mutational status.
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oBjeCtives: The introduction of innovative medical devices with high investment 
and operational costs is often delayed in countries with severe resource constraints. 
Cost-effectiveness analysis can help decision-makers to understand the economic 
value of such technologies. The purpose of our study was to compare the cost-effec-
tiveness of two modern radiation therapy techniques, the stereotactic body radiation 
therapy (SBRT) and intensity-modulated radiation therapy (IMRT) compared to the 
3-dimensional conventional radiation therapy (3DCRT) for treatment of low- to 
intermediate-risk prostate cancer in Hungary. Methods: A Markov model was 
constructed with the following disease states of a 65-year-old patient with organ 
confined prostate cancer: no evidence of disease after radiation therapy, hormone 
therapy, chemotherapy, death. Transition probabilities were calculated based on 
the international literature for SBRT, IMRT and 3DCRT. Utility values for each health 
state were obtained from publically available secondary sources. Costs in the model 
were calculated based on the Hungarian Health Insurance Fund rates, and were 
converted to EUR by applying actual exchange rates (1 EUR = 305 HUF). Analysis 
was conducted from payer perspective for 65-year-old patients over 10 years time 
horizon. Results: Based on preliminary calculations the expected mean cost of 
patients undergoing SBRT, IMRT and 3DCRT were 2,201 EUR, 5,704 EUR and 11.549 
EUR respectively. Expected QALYs were 6.00 for SBRT, 5.8 for IMRT and 3.9 for 3DCRT. 
Compared to 3DCRT, both IMRT and SBRT were less costly and resulted in more 
health gain. ConClusions: The modern SBRT and IMRT are not only cost-effective 
compared to the conventional 3DCRT but also provide a great cost saving potential 
for the Hungarian health care system and may improve access to radiation and qual-
ity of life for patients. Appropriate financial incentives in the DRG system should 
support the uptake of cost-effective hospital technologies in Hungary.
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oBjeCtives: To review the cost-effectiveness studies of chronic lymphocytic leu-
kemia (CLL) treatment, in combination and in comparison with fludarabine and 
cyclophosphamide chemotherapy (R-FC) in refractory patients or patients who had 
been previously treated. Methods: Search and analysis of scientific evidence: 
the basics of The Cochrane Library, Centre for Reviews and Dissemination (CRD), 
Embase, Lilacs, Database of the Brazilian Network for Technology Assessment 
(SISREBRATS), and MEDLINE via PubMed were searched. Aiming to meet economic 
evaluations (AVE), or evaluations of health technologies (ATS), comparing schemas 
cyclophosphamide and fludarabine (CF) and the same plus Rituximab (R-FC). Studies 
were only selected in second-line treatment for CLL. Results: Two economic evalu-
ations studied the treatment of patients with refractory or relapsing disease (R-FC 
vs FC). In the study, 24% had improvement in progression-free survival outcome (p 
< 0.05) in the R-FC, with more patients achieving partial or complete response in 
this group (61% vs 49%, p < 0.05). There was no statistically significant difference in 
overall survival. The Rituximab caused more adverse effects, but values of statistical 
tests for these outcomes are not presented. In a technology assessment conducted 
by NICE, even with reservations, the drug was recommended in view of the British 
health care system. ConClusions: There is significant uncertainty in the relevant 
outcomes for stages of refractory or relapsing disease. Few clinical trials evaluating 
the effectiveness of Rituximab in patients with CLL, which demonstrate no impact 
on overall survival, were found. In addition to the significant increase in costs for 
managing the disease.
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oBjeCtives: To analyze the cost-effectiveness of treating all chronic-phase chronic 
myeloid leukemia (CML) with imatinib initially compared to physician-choice 
between imatinib or the second-generation tyrosine kinase inhibitors (TKIs) dasat-
inib or nilotinib. Imatinib will lose patent exclusivity between 2015-2016 and its 
price is expected to drop 60-90% within one year throughout Europe. Methods: 
A Markov model simulating “step-therapy” compared to “physician-choice” in 
treating CML in 2015 through 5 years. The model assumes a European societal per-
spective. In both approaches, if initial treatment fails, patients are switched to a 
second-generation TKI. Patients are assumed to switch if they fail to meet efficacy 
endpoints: complete cytogenetic response (CCyR) or major molecular response 
